Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Telang, Sucheta ^a   Rasku, Mary A ^a   Clem, Amy L ^a   Carter, Karen ^a   Klarer, Alden C ^a   Badger, Wesley R ^a   Milam, Rebecca A ^a   Rai, Shesh N ^b   Pan, Jianmin ^b   Gragg, Hana ^a   Clem, Brian F ^a   McMasters, Kelly M ^a   Miller, Donald M ^a   Chesney, Jason ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFTITOX; ANTINEOPLASTIC AGENT; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2;

ABDOMINAL PAIN; ADULT; ARTICLE; ASCITES; BACKACHE; BONE PAIN; BREAST DISEASE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CHILL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLUID RETENTION; FOOT EDEMA; GAIT DISORDER; HUMAN; HYPOTENSION; INSOMNIA; JAUNDICE; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK PAIN; OCULAR PRURITUS; ORAL PARESTHESIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURISY; PRESYNCOPE; PRURITUS; RASH; SIDE EFFECT; SURVIVAL TIME; SWEATING; T CELL DEPLETION; THROMBOSIS; TREATMENT OUTCOME; VISUAL DISORDER; VITILIGO; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA; AGED; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SKIN TUMOR; SURVIVAL; T LYMPHOCYTE; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; KENTUCKY; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 83255164934     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-515     Document Type: Article

References (22)

1. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26(4):527-534.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17(7):2105-2116.
4. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1):7-17.
5. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18(12):2444-2458.
6. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372(9633):117-126.
7. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155-164.
8. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med
9. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(4):295-307.
10. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164.
11. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008, 20(2):241-246.
12. Jones E, Dahm-Vicker M, Golgher D, Gallimore A. CD25+ regulatory T cells and tumor immunity. Immunol Lett 2003, 85(2):141-143.
13. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
14. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 200(6):771-782.
15. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173(2):1444-1453.
16. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma 2000, 1(Suppl 1):S27-31.
17. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005, 54(6):369-377.
18. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110(9):3192-3201.
19. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6(1):1-18.
20. Gottlieb RH, Litwin A, Gupta B, Taylor J, Raczyk C, Mashtare T, Wilding G, Fakih M. Qualitative radiology assessment of tumor response: does it measure up?. Clin Imaging 2008, 32(2):136-140.
21. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28(6):582-592.
22. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007, 117(5):1167-1174.